Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

NCT03781960 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT03781960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03781960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2019
Completion date
April 29, 2022
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma